Ketamine is an established anaesthetic and analgesic used in Libyan clinical practice (hospital anaesthesia and emergency care) and appears in clinical reports and local medical literature describing its use in perioperative and emergency settings in Libya. Use as an anaesthetic conforms with international essential‑medicine guidance: ketamine is listed on the World Health Organization Model List of Essential Medicines as an injectable anaesthetic. [1]WHO Model List of Essential Medicines — ketamine listed under injectable general anaesthetics [2]Libyan clinical literature citing anaesthetic practice including ketamine
Regulatory & reimbursement context: Libya’s national drug control law criminalizes unauthorized importation, possession or trafficking of controlled psychotropic substances and provides the statutory framework under which medical use is permitted through authorised healthcare channels; however Libya does not publish a clearly defined, national reimbursement schedule for novel psychiatric indications of ketamine (e.g., intranasal/off‑label use for treatment‑resistant depression). In practice, ketamine is available and used in hospitals for anaesthesia and some off‑label uses (reported in regional clinical practice and academic articles), but there is no documented nationwide public insurance program that reimburses ketamine for psychedelic‑assisted psychiatric therapy in Libya. Public vs private nuance: because Libya’s health financing is fragmented and heavily reliant on public hospitals with variable supplies and out‑of‑pocket private care, any provision of ketamine outside standard anaesthesia is likely to be arranged on an ad‑hoc, facility level rather than via a national reimbursement policy. [3]UNODC — Libya: Law on Drugs and Fraudulent Medicines [2]Libyan clinical literature — perioperative anaesthesia study